Form 4: Rocket Pharmaceuticals Director to Receive 30,000 Restricted Stock Units

Rocket Pharmaceuticals, Inc. Director Fady Ibraham Malik is scheduled to acquire 30,000 restricted stock units, which will vest in full on June 18, 2026.

Summary

• Fady Ibraham Malik, a Director of Rocket Pharmaceuticals, Inc. (RCKT), is scheduled to acquire 30,000 restricted stock units (RSUs) on June 18, 2025.
• These RSUs convert to common stock on a one-for-one basis.
• The RSUs will vest in full on June 18, 2026.
• The acquisition price per RSU is $0, which is typical for equity grants.
• Following this planned transaction, Fady Ibraham Malik will beneficially own 30,000 common stock (in the form of RSUs).
• The transaction is indicated to be pursuant to a Rule 10b5-1(c) plan, suggesting a pre-arranged acquisition.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of continued commitment and aligns the director's interests with long-term shareholder value, indicating stability in governance and compensation practices.

Positives

• The grant of restricted stock units aligns the director's interests with the long-term performance and shareholder value of Rocket Pharmaceuticals, Inc.

Future Outlook

The document outlines a future grant of 30,000 restricted stock units to Director Fady Ibraham Malik on June 18, 2025, with full vesting scheduled for June 18, 2026. This indicates a pre-planned equity compensation event.

Industry Context

The grant of restricted stock units is a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, designed to incentivize long-term commitment and align interests with shareholder returns.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors is a standard practice across various industries, including biotechnology, to attract and retain talent while aligning their financial interests with the company's long-term performance.
• While specific comparable companies or projects are not detailed in this filing, such grants are consistent with compensation structures observed at similar-stage biotech firms aiming for sustained growth and innovation.

Related Party Transactions

• The acquisition of restricted stock units by a director constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be viewed positively as it aligns the director's financial interests with the long-term success of the company, potentially leading to more focused decision-making aimed at increasing shareholder value.

Next Steps

• The 30,000 restricted stock units are scheduled to vest in full on June 18, 2026.

Key Dates

Recommendation

Keywords

Rocket Pharmaceuticals, RCKT, SEC Form 4, insider transaction, restricted stock units, RSU, equity compensation, director, stock grant, 10b5-1 plan